GlaxoSmithKline’s (GSK) COVID-19 vaccine candidate developed with SK bioscience has been submitted for regulatory approval in South Korea after positive phase-III clinical data, the British drugmaker said yesterday.
GSK said that SK bioscience will also apply to the World Health Organization (WHO) for Emergency Use Listing (EUL) and seek authorisations at individual regulatory agencies around the world.
The company said an extended clinical trial is planned to test the vaccine’s effectiveness against the Omicron variant of the virus.
Edits by EP News Bureau